MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. LGVN (“Longeveron” or the “Company”), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs, today announced that management will attend three upcoming investor conferences.

AGP Virtual Biotech Conference
Format: one-on-one calls
Date: Wednesday 30 November 2022
Location: Virtual

The Benchmark Company 11th Annual Discovery One-on-One Investor Conference
Format: one-on-one calls
Date: Thursday 1st December 2022
Location: New York, NY

RHK Disruptive Growth Conference 2022
Format: company presentation
Date: Tuesday, December 6, 2022
Location: New York, NY
Time: 10:40-11:00 a.m. ET

A live webcast of the presentation at the RHK 2022 Disruptive Growth Conference can be accessed under “Events & Presentations” on the Investors section of Longeveron’s website at https://investors.longeveron.com/events-and-presentations/default.aspx. A replay of the webcast will be available shortly after the conference.

About Longeveron Inc.
Longeveron is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medical signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multimodal mechanism of action that is provascular, proregenerative and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease and Old Age. More information about the company can be found at www.longeveron.com.

Investor contact:

Elsie Yau
Star IR, Inc.
212-698-8700
elsie.yau@sternir.com

Source: Longeveron Inc